Filter Results
:
(564)
Show Results For
-
All HBS Web
(564)
- People (4)
- News (138)
- Research (341)
- Events (2)
- Multimedia (4)
- Faculty Publications (165)
Show Results For
-
All HBS Web
(564)
- People (4)
- News (138)
- Research (341)
- Events (2)
- Multimedia (4)
- Faculty Publications (165)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Biotechnology Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- February 2024
- Article
Representation and Extrapolation: Evidence from Clinical Trials
By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams
This article examines the consequences and causes of low enrollment of Black patients in clinical
trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is
more relevant for decision-making by physicians and patients when it...
View Details
Keywords:
Representation;
Racial Disparity;
Health Testing and Trials;
Race;
Equality and Inequality;
Innovation and Invention;
Pharmaceutical Industry
Alsan, Marcella, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein, and Heidi L. Williams. "Representation and Extrapolation: Evidence from Clinical Trials." Quarterly Journal of Economics 139, no. 1 (February 2024): 575–635.
- 23 Jun 2015
- Video
Innovations Wanted: Beating Brain Disease
- January 2018
- Supplement
BeiGene Supplemental PowerPoint
By: Willy C. Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window...
View Details
- April 2017
- Supplement
Imprimis (D)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also...
View Details
Keywords:
Decision Choices and Conditions;
Growth and Development Strategy;
Pharmaceutical Industry;
United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (D)." Harvard Business School Supplement 717-498, April 2017.
- November 2017
- Case
BeiGene
By: Willy Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window...
View Details
Keywords:
Biotechnology;
Pharmaceutical Company;
Pharmaceuticals;
China;
Regulatory Environment;
Business Strategy;
Business Startups;
Innovation Strategy;
Situation or Environment;
Pharmaceutical Industry;
China
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.
- 12 Nov 2019
- Video
Kiran Mazumdar Shaw
Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, explains how her firm developed over four years a new technology for making insulin, an essential...
View Details
- 18 Dec 2018
- First Look
New Research and Ideas, December 18, 2018
R&D-intensive firms react to negative shocks to their existing products? We explore this question using detailed project-level data from drug development firms. Using FDA Public Health Advisories as an...
View Details
Keywords:
Dina Gerdeman
- October 2012
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)
By: Toby Stuart and James Weber
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel...
View Details
Keywords:
Business Startups;
Decision Choices and Conditions;
Entrepreneurship;
Growth and Development Strategy;
Risk Management;
Brands and Branding;
Pharmaceutical Industry
Stuart, Toby, and James Weber. "Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)." Harvard Business School Case 813-029, October 2012.
- March 2008 (Revised June 2008)
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel...
View Details
Keywords:
Business Startups;
Decision Choices and Conditions;
Entrepreneurship;
Growth and Development Strategy;
Risk Management;
Brands and Branding;
Pharmaceutical Industry
Stuart, Toby, and David Kiron. "Sirtris Pharmaceuticals: Living Healthier, Longer." Harvard Business School Case 808-112, March 2008. (Revised June 2008.)
- Profile
Avi Kremer
millions of dollars into research, and removed critical barriers to the development of treatments. “Our focus was to get drug companies to invest money in ALS,” says Kremer, who was diagnosed in 2004, just...
View Details
- September 1993
- Case
Manufacturing at ALZA: The Right Prescription? (A)
ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner...
View Details
Keywords:
Business or Company Management;
Technological Innovation;
Innovation and Management;
Growth and Development Strategy;
Problems and Challenges;
Production;
Research and Development;
Organizational Change and Adaptation;
Pharmaceutical Industry;
Medical Devices and Supplies Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (A)." Harvard Business School Case 694-019, September 1993.
- 14 Jul 2023
- Video
BiGS Idea: Rethinking Health Equity
- 10 Aug 2015
- Research & Ideas
New Medical Devices Get To Patients Too Slowly
While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market, the opposite seems to have occurred in the agency's approval of...
View Details
- 06 Mar 2020
- News
How Medical Nonprofits Set Winning Strategy
- 19 Dec 2018
- Working Paper Summaries
Find and Replace: R&D Investment Following the Erosion of Existing Products
- 2021
- Working Paper
SSRIs and Non-SSRIs (through 1999): Case Histories of Significant Medical Advances
By: Amar Bhidé, Srikant M. Datar and Katherine Stebbins
Our case history describes the development of Prozac, a blockbuster drug that transformed the treatment of depression – and became a cultural phenomenon in the United States. Specifically, we chronicle the: 1) prior treatments for depression and the research that...
View Details
Keywords:
Health Care and Treatment;
Technological Innovation;
Innovation Strategy;
Technology Adoption;
Collaborative Innovation and Invention;
Innovation and Invention;
Governing Rules, Regulations, and Reforms
Bhidé, Amar, Srikant M. Datar, and Katherine Stebbins. "SSRIs and Non-SSRIs (through 1999): Case Histories of Significant Medical Advances." Harvard Business School Working Paper, No. 20-135, July 2020. (Revised June 2021.)
- September 2017
- Case
Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry
By: Steven Rogers and Alyssa Haywoode
Dr. William Carson, an African-American alum of Harvard University became the President and CEO of a multi billion dollar division of Otsuka, a Japan based pharmaceutical company. His ascension to this leadership position followed a thriving career in academic medicine...
View Details
Keywords:
Dr. Williams Carson;
Otsuka America Pharmaceutical;
Harvard;
Abilify;
Aripiprazole;
Health Testing and Trials;
Globalized Firms and Management;
Globalized Markets and Industries;
Cross-Cultural and Cross-Border Issues;
Decision Choices and Conditions;
Pharmaceutical Industry;
Japan
Rogers, Steven, and Alyssa Haywoode. "Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry." Harvard Business School Case 318-005, September 2017.
- January 2001
- Case
Merck Global Health Initiatives (A)
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,...
View Details
Keywords:
Programs;
Philanthropy and Charitable Giving;
Health Disorders;
Health Care and Treatment;
Private Sector;
Public Sector;
Alliances;
Problems and Challenges;
Pharmaceutical Industry;
Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (A)." Harvard Business School Case 301-088, January 2001.
- March 1999 (Revised June 2000)
- Case
Eli Lilly: The Evista Project
By: Steven C. Wheelwright and Matt Verlinden
Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)...
View Details
Keywords:
Projects;
Groups and Teams;
Operations;
Management Teams;
Product Development;
Transition;
Product Design;
Business Startups;
Business Plan;
Product Launch;
Competition;
Service Operations;
Pharmaceutical Industry
Wheelwright, Steven C., and Matt Verlinden. "Eli Lilly: The Evista Project." Harvard Business School Case 699-016, March 1999. (Revised June 2000.)